# Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement

> **NCT02462837** · PHASE2 · TERMINATED · sponsor: **Southern Illinois University** · enrollment: 11 (actual)

## Conditions studied

- Urinary Bladder, Overactive
- Pain
- Lower Urinary Tract Symptoms

## Interventions

- **DRUG:** Mirabegron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02462837
- **Lead sponsor:** Southern Illinois University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2019-01-30
- **Final completion:** 2019-01-30
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** insufficient rate of accrual
- **Last updated:** 2023-06-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02462837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02462837, "Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02462837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*